Intesive fludarabine-high dose cytarabine-idarubicin combination as induction therapy with risk-adapted consolidation may improve treatment efficacy in younger Acute Myeloid Leukemia (AML) patients: Rationales, evidences and future perspectives

Fabio Guolo, Paola Minetto, Marino Clavio, Maurizio Miglino, Roberto Massimo Lemoli, Marco Gobbi

Research output: Contribution to journalComment/debatepeer-review

Fingerprint

Dive into the research topics of 'Intesive fludarabine-high dose cytarabine-idarubicin combination as induction therapy with risk-adapted consolidation may improve treatment efficacy in younger Acute Myeloid Leukemia (AML) patients: Rationales, evidences and future perspectives'. Together they form a unique fingerprint.

Medicine & Life Sciences

Social Sciences

Chemical Compounds